An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)
Mark M. Awad, Quincy S.C. Chu, Leena Gandhi, Joe J. Stephenson, Ramaswamy Govindan, Daniel S. Bradford, Philip D. Bonomi, David M. Ellison, Keith D. Eaton, Holger Fritsch, Gerd Munzert, Bruce E. Johnson, Mark A. Socinski
Dive into the research topics of 'An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)'. Together they form a unique fingerprint.